A targeted medicine for selected blood cancers and chronic graft-versus-host disease.
Profile scope: Ibrutinib. Confirm the exact product and route; formulations and combination products are not interchangeable.
Possible side effects
Digestive symptoms, mouth soreness, fatigue, or muscle discomfort may occur.
Serious risks and warning signs
Major bleeding, serious infection, abnormal rhythms, liver-related symptoms, or neurological changes need prompt assessment. The source also describes additional-cancer concerns. Review procedures and interacting medicines with the treating team.
A question for your healthcare team
What monitoring and procedure precautions apply, and which bleeding, pulse, or infection changes require immediate contact?
What to do with this information
Discuss persistent or troubling symptoms with your prescriber or pharmacist. For severe breathing difficulty, collapse, a seizure, or inability to wake someone, seek emergency help. Read the linked medicine information for drug-specific instructions, including situations requiring immediate action. For routine treatment changes, consult your prescriber rather than changing your dose on your own. Follow the urgent action instructions above and in the linked medicine information.
Sources
Sources checked November 20, 2026. An original AI-assisted educational summary, not a complete adverse-effect or interaction list. This profile is part of the broader library expansion, not the original prescription-use ranking. Inclusion does not confirm current product availability or mean that risks outweigh benefits. This page has not been independently reviewed by a clinician.